JP2012522754A5 - - Google Patents

Download PDF

Info

Publication number
JP2012522754A5
JP2012522754A5 JP2012502694A JP2012502694A JP2012522754A5 JP 2012522754 A5 JP2012522754 A5 JP 2012522754A5 JP 2012502694 A JP2012502694 A JP 2012502694A JP 2012502694 A JP2012502694 A JP 2012502694A JP 2012522754 A5 JP2012522754 A5 JP 2012522754A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
disease
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012502694A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012522754A (ja
JP5810076B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/054418 external-priority patent/WO2010115843A2/en
Publication of JP2012522754A publication Critical patent/JP2012522754A/ja
Publication of JP2012522754A5 publication Critical patent/JP2012522754A5/ja
Application granted granted Critical
Publication of JP5810076B2 publication Critical patent/JP5810076B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012502694A 2009-04-03 2010-04-01 薬学的組成物 Active JP5810076B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09157303.0 2009-04-03
EP09157303 2009-04-03
PCT/EP2010/054418 WO2010115843A2 (en) 2009-04-03 2010-04-01 Pharmaceutical composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015129383A Division JP2015214559A (ja) 2009-04-03 2015-06-29 薬学的組成物

Publications (3)

Publication Number Publication Date
JP2012522754A JP2012522754A (ja) 2012-09-27
JP2012522754A5 true JP2012522754A5 (https=) 2013-05-09
JP5810076B2 JP5810076B2 (ja) 2015-11-11

Family

ID=42269736

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012502694A Active JP5810076B2 (ja) 2009-04-03 2010-04-01 薬学的組成物
JP2015129383A Withdrawn JP2015214559A (ja) 2009-04-03 2015-06-29 薬学的組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015129383A Withdrawn JP2015214559A (ja) 2009-04-03 2015-06-29 薬学的組成物

Country Status (28)

Country Link
US (3) US8647631B2 (https=)
EP (2) EP2413957B1 (https=)
JP (2) JP5810076B2 (https=)
KR (2) KR20150041203A (https=)
CN (2) CN105524160B (https=)
AU (1) AU2010233856B2 (https=)
BR (1) BRPI1015088B1 (https=)
CA (1) CA2757345C (https=)
CL (2) CL2011002457A1 (https=)
CO (1) CO6390113A2 (https=)
CR (1) CR20110509A (https=)
DK (2) DK2413957T3 (https=)
EC (1) ECSP11011367A (https=)
ES (2) ES2738623T3 (https=)
HU (2) HUE044981T2 (https=)
IL (1) IL215451A (https=)
MA (1) MA34120B1 (https=)
MX (1) MX2011010353A (https=)
MY (1) MY171300A (https=)
NZ (1) NZ595856A (https=)
PL (2) PL3097925T3 (https=)
PT (2) PT2413957T (https=)
RU (1) RU2582916C2 (https=)
SG (1) SG175037A1 (https=)
SI (2) SI2413957T1 (https=)
UA (1) UA107571C2 (https=)
WO (1) WO2010115843A2 (https=)
ZA (1) ZA201107776B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
HUE055739T2 (hu) * 2009-03-18 2021-12-28 Ac Immune Sa Eljárás terápiás alkalmazásra
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CN106390107B (zh) * 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
WO2012020124A1 (en) * 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
MY164376A (en) * 2010-10-07 2017-12-15 Univ Leuven Kath Phosphospecific antibodies recognizing tau
JP6027011B2 (ja) 2010-10-26 2016-11-16 エーシー イミューン ソシエテ アノニム 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
ME03008B (me) * 2011-09-19 2018-10-20 Axon Neuroscience Se Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
KR101981351B1 (ko) 2011-10-07 2019-09-02 에이씨 이뮨 에스.에이. 타우를 인식하는 포스포특이적 항체
RU2644242C2 (ru) 2012-04-05 2018-02-08 Ац Иммуне С.А. Гуманизированное тау-антитело
PL2857039T3 (pl) * 2012-05-31 2020-05-18 Osaka City University Środek terapeutyczny lub środek profilaktyczny na otępienie
SG10201708959WA (en) 2012-07-03 2017-11-29 Univ Washington Antibodies to tau
NZ630542A (en) * 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
WO2014150877A2 (en) * 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
AU2014368696A1 (en) 2013-12-20 2016-06-02 F. Hoffmann-La Roche Ag Humanized anti-Tau(pS422) antibodies and methods of use
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン,インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI734975B (zh) 2014-06-27 2021-08-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
CN107073297B (zh) * 2014-07-08 2021-09-14 纽约大学 Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對tau之抗體及其用途
NZ775762A (en) 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
WO2016207245A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
US10344081B2 (en) 2015-07-06 2019-07-09 Ucb Biopharma Sprl Tau-binding antibodies
WO2017027685A2 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
CA3032692A1 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination antibody therapy for the treatment of neurodegenerative diseases
IL266862B2 (en) 2016-12-01 2024-01-01 Sangamo Therapeutics Inc Tau modulators and methods and preparations for their administration
UA128383C2 (uk) 2016-12-07 2024-07-03 Дженентек, Інк. Антитіло до тау-білка та спосіб його застосування
MX2019006330A (es) 2016-12-07 2019-09-26 Genentech Inc Anticuerpos anti-tau y metodos de uso.
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
CN111787942B (zh) 2017-10-25 2024-03-29 杨森制药公司 磷酸化Tau肽的组合物及其用途
CA3107788A1 (en) 2018-07-31 2020-02-06 Eli Lilly And Company Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation
WO2020072677A1 (en) 2018-10-02 2020-04-09 Sangamo Therapeutics, Inc. Methods and compositions for modulation of tau proteins
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
MY206596A (en) * 2019-02-08 2024-12-25 Janssen Pharmaceuticals Inc Method of safe administration of phosphorylated tau peptide vaccine
JOP20210284A1 (ar) * 2019-04-24 2023-01-30 Janssen Pharmaceuticals Inc الإعطاء غير المتجانس للقاحات تاو
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
CA3183835A1 (en) 2020-06-25 2021-12-30 Jeanne E. Baker High affinity antibodies targeting tau phosphorylated at serine 413
WO2022144406A1 (en) * 2020-12-29 2022-07-07 Neurimmune Ag Human anti-tau antibodies
EP4486389A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate comprising at least a beta-glucan
KR102856378B1 (ko) * 2022-09-30 2025-09-08 주식회사 젬백스앤카엘 4r 타우병증의 치료 또는 예방용 펩티드
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
WO1994013795A1 (en) * 1992-12-14 1994-06-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US20020086009A1 (en) 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
AU5508798A (en) * 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
PT1036092E (pt) * 1997-12-03 2005-09-30 Biogen Inc Compos~icoes e metodos de proteinas hidrofobicamente modificadas
JP2004503747A (ja) 2000-07-11 2004-02-05 モレキュラー ジェリアトリクス コーポレイション 結合物質の同定するための試薬と方法
AU2003292936A1 (en) 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US20050261475A1 (en) * 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
KR101152557B1 (ko) * 2005-12-12 2012-09-07 에이씨 이뮨 에스.에이. 치료 백신
WO2007068105A1 (en) * 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
CN101965365A (zh) 2007-10-19 2011-02-02 伊缪纳斯制药株式会社 能够特异性结合Aβ寡聚体的抗体及其应用
HUE055739T2 (hu) * 2009-03-18 2021-12-28 Ac Immune Sa Eljárás terápiás alkalmazásra
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CN106390107B (zh) 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
JP2013500326A (ja) 2009-07-30 2013-01-07 ファイザー バクシーンズ エルエルシー 抗原性タウペプチドおよびその使用

Similar Documents

Publication Publication Date Title
JP2012522754A5 (https=)
JP7539446B2 (ja) 病理学的タウタンパク質の免疫学的標的化方法
JP5419131B2 (ja) 治療的特性を有するβ1〜42特異的モノクローナル抗体
RU2011144307A (ru) Фармацевтическая композиция
JP2014087353A (ja) モノクローナル抗βアミロイド抗体
JP2011522842A (ja) パーキンソン病に関連する症状の治療のための化合物
AU2012244075B2 (en) A beta 1-42 specific monoclonal antibodies with therapeutic properties
AU2015201763A1 (en) A beta 1-42 specific monoclonal antibodies with therapeutic properties
HK1204579B (en) A beta 1-42 specific monoclonal antibodies with therapeutic properties
HK1124532A (en) A beta 1-42 specific monoclonal antibodies with therapeutic properties
HK1161141B (en) A beta 1-42 specific monoclonal antibodies with therapeutic properties
HK1127486B (zh) 治疗性疫苗
HK1127486A1 (en) Therapeutic vaccine